75. クッシング病 Cushing disease Clinical trials / Disease details

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-004497-15-IT (EUCTR)	12/12/2016	08/01/2018	Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs	Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing’s Syndrome-Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs - Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs	Cushing’s Syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE Product Name: Tadalafil	UMBERTO I - POLICLINICO DI ROMA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 2	Italy
2	NCT02611258 (ClinicalTrials.gov)	July 2016	16/11/2015	Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs	Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome	Cushing's Syndrome Cardiomyopathy	Drug: Tadalafil	Andrea M. Isidori	NULL	Unknown status	18 Years	75 Years	All	18	Phase 2	Italy